Garman Katherine S, Nevins Joseph R, Potti Anil
Duke Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, NC 27710, USA.
Hum Mol Genet. 2007 Oct 15;16 Spec No. 2:R226-32. doi: 10.1093/hmg/ddm184.
Numerous recent studies have demonstrated the use of genomic data, particularly gene expression signatures, as clinical prognostic factors in cancer and other complex diseases. These studies highlight the opportunity for strategies to achieve truly personalized cancer treatment. In particular, the ability to develop gene expression signatures will likely allow us to guide the use of currently available cancer drugs, develop new targeted therapeutics, and provide an opportunity to better match the most effective drug or drugs with the molecular characteristics of the individual patient.
最近的大量研究表明,基因组数据,尤其是基因表达特征,可作为癌症和其他复杂疾病的临床预后因素。这些研究凸显了实现真正个性化癌症治疗策略的机遇。特别是,开发基因表达特征的能力可能使我们能够指导当前可用癌症药物的使用,开发新的靶向疗法,并提供机会更好地将最有效的一种或多种药物与个体患者的分子特征相匹配。